Image Source: Pixabay

The 5 constituents in the munKNEE Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week going DOWN 6.5%, UP 22.0%, DOWN 7.7% and UP 1.6% in the past 4 weeks and is now DOWN 7.4% so far this week. The culprit this week is GH Resources (GHRS) whose stock price finally responded to its extremely disappointing Q3 Financial results (see below). Here's how they rank, in ascending order, according to their performances this week, last week and YTD with any pertinent news.

1. GH Research (GHRS): DOWN 18.8% this week; UP 3.0% last week; DOWN 27.6% YTD
   • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Read: GH Research Reports Third Quarter Financial Results and Provides Business Updates
2. Atai Life Sciences (ATAI): DOWN 1.8% this week; DOWN 5.1% last week; DOWN 57.8% YTD
   • is focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read: atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
3. Compass Pathways (CMPS): UP 0.7% this week; UP 0.7% last week; DOWN 22.5% YTD
   • is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Read: Compass Pathways PLC (CMPS) Reports Q3 2023 Financial Results and Business Highlights
4. Incannex Healthcare (IXHL): UP 1.1% this week; DOWN 18.8% last week; DOWN 67.1% YTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Read: Federal Court of Australia Approves Incannex’s Re-Domiciliation To USA
5. Mind Medicine (MNMD): UP 6.2% this week; UP 3.6% last week; UP 26.1% YTD
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read: MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Summary

The munKNEE Psychedelic Drug Stocks Index was DOWN 7.4% this week, UP 1.6% the previous week and DOWN 7.7% the week before. The Index is now DOWN 28.9% YTD.

If you are interested in the cannabis category, consider the AdvisorShares Psychedelic ETF (PSIL) which is UP 3.8% so far week but is still DOWN 31.8% YTD.

More By This Author:

Nvidia Reports 34% Increase In Q3 Revenue; Expects Trend To Continue In Q4
Ayr Wellness Reports Q3 Operating Loss Reduced By 67% But A Negative Outlook For Q4
The Micro & Small Cap AI Stocks Index Was Up 13.5% Last Week; Now Up 175.5% YTD